ICAM, a recent advance in patient care for COVID-19
AdventHealth Ocala, a Seventh-Day Adventist Medical institution in Orlando, Florida; has been having excellent successes in a treatment combination that it names, ICAM. This is a combination of immunosupport with vitamins and zinc; a corticosteroid to reduce inflammation in the lungs; an anticoagulant to foster blood thinning and; Macrolide, an antibiotic to counter pneumonia.
Over the reported 76 days of trial, the institution has had 96.4% success rate on 100 patients. They have avoided the mechanical ventilators, and within 14 days patients are discharged. There have been no associated deaths.
This trial was born out of the shortage of the FDA prescribed drugs and was spearheaded by its lead pharmacist, Dr. Carlette Norwood-Williams.
More recently, it offers remote At-Home patient-care for persons with COVID-19.